Table 3.

Percent incidence rates overweight (≥85th BMI-for-chronological-age percentile) and height-age-overweight (≥85th BMI-for-height-age percentile)

	Salt wasting	Simple virilizing
Sample size (N = 194)	124	70
Overweight (%)	70	73
Height-age-overweight (%)	71	70
Three or more height-age-overweight measurements (%)	35	33
Height-age-overweight by birth era (%)
1970–1994 (n = 133)	73	71
1994–2013 (n = 61)	68	64
Incidence of height-age-overweight among children observed in each age interval(%)
2–5 years	48	41
6–11 years	59	47
12–18 years	39	50
Prevalence of overweight or obesity in US children (NHANES 2011–201233; %)
2–5 years	23
6–11 years	34
12–19 years	35
Incidence of height-age-overweight by hydrocortisone (HC) dose†
HC < 15 mg/m2/day	11 (7–16)	14 (6–33)
HC ≥ 15 mg/m2/day	14 (9–23)	8 (3–20)
Incidence of height-age-overweight by hydrocortisone (HC) and fludrocortisone (F) dose†
HC < 15 mg/m2/day, no F	23 (10–51)
HC ≥ 15 mg/m2/day, no F	19 (9–40)
HC < 15 mg/m2/day, with F	10 (7–15)
HC ≥ 15 mg/m2/day, with F	10 (6–17)
Age 2–5 years: Height-age-overweight by measurements of 17 OHP <400 ng/dl‡ (%)
<3	36*
3 or more	56*
Age 6–11 years: Height-age-overweight by measurements of 17 OHP <400 ng/dl‡ (%)
<3	54
3 or more	55

Rates were compared between CAH subtypes, between hydrocortisone and fludrocortisone dose groups and between those with <3 and 3 or more measurements of 17 OHP <400 ng/dl.

^†Values are incidence rates per 100 patient years (95% confidence interval). Restricted to children aged 2–9 years old; all SW children received fludrocortisone.

^‡Restricted to subjects with at least 3 measurements of 17-OHP; 400 ng/dl of 17OHP =12.12 nmol/l. (ng/dl × 0.0303 = nmol/l).

^*Incidence lower in children with <3 such measurements (P = 0.021).